CMS-Blessed Warfarin Genetic Testing Trial Aimed At Winning Over Payers and Docs
This article was originally published in The Pink Sheet Daily
Executive Summary
Genetic testing to guide dosing of warfarin is still relevant, even with new competing oral anticoagulants on the rise, says the CEO of Iverson, the diagnostics company sponsoring the trial.
You may also be interested in...
CMS Sets The Stage For New Medicare "Coverage With Evidence Development" Guidance
A rarely-used tool for gathering data on medical technologies will get a fresh look as the agency solicits public comment on how to make CED a more meaningful and effective part of its coverage decision-making process.
With Pradaxa On The Rise, Medco Gathers Evidence On Warfarin Diagnostic Testing
Pharmacy benefits management company Medco Health Solutions Inc. says that with the newly approved oral anticoagulant Pradaxa (dabigatran) off to a good commercial start, it plans to monitor outcomes and compare results with generic warfarin that has been optimized according to genetic testing.
With Pradaxa On The Rise, Medco Gathers Evidence On Warfarin Diagnostic Testing
Pharmacy benefits management company Medco Health Solutions Inc. says that with the newly approved oral anticoagulant Pradaxa (dabigatran) off to a good commercial start, it plans to monitor outcomes and compare results with generic warfarin that has been optimized according to genetic testing.